CPA
SLDB icon

Capital Performance Advisors’s Solid Biosciences SLDB Stock Holding History

Capital Performance Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$105 – 2273
2024
Q3 		$105 Buy
+15
New +$122 ﹤0.01% 2688

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Performance Advisors's SLDB Position: Q4 2024 in Review

Capital Performance Advisors sold out of Solid Biosciences (SLDB) in Q4 2024, closing a stake of 15 shares — an estimated $105 sold.

Capital Performance Advisors first reported a position in SLDB in Q3 2024 and held it in 1 quarter. The position peaked at $105 in Q3 2024. 90 funds tracked by Wall St. Rank hold SLDB as of Q4 2024.

  • Capital Performance Advisors reported no remaining Solid Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 15 Solid Biosciences shares in Q4 2024, an estimated $105.
  • Capital Performance Advisors first reported a position in Solid Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Solid Biosciences position peaked at $105 in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.